Rallybio Corp. (RLYB) Stock: Dividends & Earnings

Company Overview:

Market Cap: $95.52M

Trailing PE: N/A

FWD PE: —

Payout Ratio (TTM): —

52-Week Range: $3.67 - $17.57

5.2 Year RLYB Performance Metrics:

Total Return (with DRIP): -85.1% (-30.70% CAGR)

Total Return (no DRIP): -85.1% (-30.70% CAGR)

Share Price: -85.1% (-30.70% CAGR)

Yield on Cost (with DRIP): —

Total Invested: $10,000

Total Value (with DRIP): $1,486

Total Return $ (with DRIP): -$8,514

RLYB Total Return

1M 3M 6M YTD 1Y 3Y 5Y 10Y

RLYB Price Chart

1M 3M 6M YTD 1Y 3Y 5Y 10Y All

Unlock All Reports & Research Dividend Stocks like a BOSS!

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Projected Future Returns & Dividends for RLYB

Based on past 5.2-year performance, here are RLYB growth metrics:

Share price CAGR of -30.7%
Dividend CAGR of +0%

Using RLYB CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:

	RLYB (DRIP)	RLYB - No DRIP
Current Price	$16.76	$16.76
Start Shares	596.66	596.66
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	596.66	596.66
Dividends Payment	$0.00	$0.00
Annual Dividends	$0	$0
Yield on cost	0.00%	0.00%
Share Price	$0.43	$16.76
Total Dividends	$0	$0
Final Value	$256	$10,000

Estimated Future Value + Dividends - RLYB

NOTE: Above numbers are our estimate based on RLYB's Dividend and Price CAGR over past 5.2 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

PRO

$171 ($14.25/mo) $102.60/yr ($8.55/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Buy/Sell Signals Dashboard
Stock Fundamentals
Compare Stocks Side-by-Side
Revenue & EPS Estimates
DCF Valuation Modeling

Try it free for 7 days

You save $125.40 (55%)

Company Info

Rallybio Corp. (RLYB) had its IPO on , and is traded on NASDAQ stock exchange.

Rallybio Corp. is a clinical-stage biotechnology company focused on developing and commercializing therapies for severe and rare diseases. The company’s current pipeline centers on areas such as complement dysregulation, hematology, maternal-fetal health, and iron overload disorders. Its lead programs include RLYB116, a complement component 5 inhibitor being developed for diseases driven by complement dysregulation, and RLYB332, a preclinical antibody candidate for iron overload-related conditions. Rallybio also works on therapies for rare maternal-fetal disorders, reflecting its emphasis on areas with significant unmet medical need. Headquartered in New Haven, Connecticut, Rallybio operates as a focused drug development company in the biotechnology sector, advancing specialized treatments designed for patients with serious, underserved conditions.

RLYB website: https://www.rallybio.com